Universitat de Barcelona, Barcelona, Spain
MPH, Postdoctoral Fellowship
Johns Hopkins University, Baltimore, MD, USA
Susana Perez-Gutthann, MD, PhD, MPH, FISPE, FRCP, is Vice President and Global Head of Epidemiology at RTI-HS. Dr. Perez-Gutthann holds medical and doctoral degrees from the University of Barcelona, and a Master of Public Health with a concentration in epidemiology from Johns Hopkins University. Her prior positions include Global Head of epidemiology at Pharmacia, Novartis, and Ciba-Geigy; European Head of Epidemiology at Pfizer; and a postdoctoral fellow in the Division of Clinical Epidemiology at Johns Hopkins. Dr. Perez-Gutthann has over 25 years of experience in the research-driven international pharmaceutical environment, developing and leading teams of epidemiologists and driving strategy and research programs for safety, pharmacovigilance, risk management, development, and regulatory activities applying public health and epidemiologic methods.
Dr. Perez-Gutthann is an active leader and past president of the International Society of Pharmacoepidemiology (ISPE) and past Vice-Chair of the Steering Committee of the European Medicines Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). She is a fellow of ISPE and of the Royal College of Physicians, Edinburgh. She is often invited to teach in academic programs (most recently the London School of Hygiene and Public Health) and to speak at and chair conferences and symposia. Dr. Perez-Gutthann's roles as an advisor and participant in international working groups have included ENCePP research guidance, World Health Organization (WHO), International Scientific Advisory Board to the Medicines and Healthcare Products Regulatory Agency (MHRA) General Practice Research Database, ISPE Working Groups on Risk Management Guidances (Food and Drug Administration, European Medicines Agency), Good Pharmacoepidemiology Practice, and confidentiality of patient databases in Europe. Currently, Dr. Perez-Gutthann serves as a member and chair of several scientific advisory boards for studies, research programs, and strategic and regulatory risk management topics.